Martiney J A, Cerami A, Slater A F
Picower Institute for Medical Research, Manhasset, NY 11030, USA.
Mol Med. 1996 Mar;2(2):236-46.
Human falciparum malaria, caused by the intracellular protozoa Plasmodium falciparum, results in 1-2 million deaths per year. P. falciparum digests host erythrocyte hemoglobin within its food vacuole, resulting in the release of potentially toxic free heme. A parasite-specific heme polymerization activity detoxifies the free heme by cross-linking the heme monomers to form hemozoin or malaria pigment. This biochemical process is the target of the widely successful antimalarial drug chloroquine, which is rapidly losing its effectiveness due to the spread of chloroquine resistance. We have shown that chloroquine resistance is not due to changes in the overall catalytic activity of heme polymerization or its chloroquine sensitivity. Therefore, the heme polymerization activity remains a potential target for novel antimalarials. In this study, we investigated the ability of heme analogs to inhibit heme polymerization and parasite growth in erythrocytes.
Incorporation of radioactive hemin substrate into an insoluble hemozoin pellet was used to determine heme polymerization. Incorporation of radioactive hypoxanthine into the nucleic acid of dividing parasites was used to determine the effects of heme analogs on parasite growth. Microscopic and biochemical measurements were made to determine the extent of heme analog entry into infected erythrocytes.
The heme analogs tin protoporphyrin IX (SnPP), zinc protoporphyrin IX (ZnPP), and zinc deuteroporphyrin IX, 2,4 bisglycol (ZnBG) inhibited polymerization at micromolar concentrations (ZnPP << SnPP < ZnBG). However, they did not inhibit parasite growth since they failed to gain access to the site of polymerization, the parasite's food vacuole. Finally, we observed high ZnPP levels in erythrocytes from two patients with beta-thalassemia trait, which may inhibit heme polymerization.
The heme analogs tested were able to inhibit hemozoin formation in Plasmodium falciparum trophozite extracts. The increased ZnPP levels found in thalassemic erythrocytes suggest that these may contribute, at least in part, to the observed antimalarial protection conferred by the beta-thalassemia trait. This finding may lead to the development of new forms of antimalarial therapy.
由细胞内原生动物恶性疟原虫引起的人类恶性疟疾每年导致100万至200万人死亡。恶性疟原虫在其食物泡内消化宿主红细胞血红蛋白,导致潜在有毒的游离血红素释放。一种寄生虫特异性的血红素聚合活性通过使血红素单体交联形成疟原虫色素或疟色素来解毒游离血红素。这一生物化学过程是广泛使用且成功的抗疟药物氯喹的作用靶点,由于氯喹耐药性的传播,该药物正迅速失去其有效性。我们已经表明,氯喹耐药性并非由于血红素聚合的整体催化活性或其对氯喹的敏感性发生变化。因此,血红素聚合活性仍然是新型抗疟药物的潜在靶点。在本研究中,我们研究了血红素类似物抑制血红素聚合和红细胞内寄生虫生长的能力。
将放射性血红素底物掺入不溶性疟原虫色素沉淀中用于测定血红素聚合。将放射性次黄嘌呤掺入分裂寄生虫的核酸中用于测定血红素类似物对寄生虫生长的影响。进行显微镜和生化测量以确定血红素类似物进入受感染红细胞的程度。
血红素类似物锡原卟啉IX(SnPP)、锌原卟啉IX(ZnPP)和锌中卟啉IX,2,4 - 双二醇(ZnBG)在微摩尔浓度下抑制聚合(ZnPP << SnPP < ZnBG)。然而,它们并未抑制寄生虫生长,因为它们无法进入聚合位点,即寄生虫的食物泡。最后,我们在两名β地中海贫血特征患者的红细胞中观察到高ZnPP水平,这可能抑制血红素聚合。
所测试的血红素类似物能够抑制恶性疟原虫滋养体提取物中的疟原虫色素形成。在地中海贫血红细胞中发现的ZnPP水平升高表明,这些可能至少部分地促成了观察到的β地中海贫血特征所赋予的抗疟保护作用。这一发现可能会导致新型抗疟疗法的开发。